Amidst controversy, the FDA finally approved the controversial prostate cancer therapy. Hopes are high that Provenge represents the first in a long line of effective immunotherapeutics.
Jonathan S. Batchelor
Advertisement
Articles by Jonathan S. Batchelor
Advertisement
Latest Updated Articles
Provenge wild ride blazes trail for immunotherapyPublished: December 6th 2010 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
2
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
3
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
